News & Updates
Filter by Specialty:
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
Upadacitinib treatment for atopic dermatitis (AD) may cause acne as a side effect, though this is usually only mild or moderate in severity and can be managed by topical intervention, reports a recent study.
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
23 Jun 2022
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
20 Jun 2022
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
20 Jun 2022
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.
